CN1310620A - 利用葡萄糖摄入增强剂减少编程性细胞死亡 - Google Patents

利用葡萄糖摄入增强剂减少编程性细胞死亡 Download PDF

Info

Publication number
CN1310620A
CN1310620A CN99808983A CN99808983A CN1310620A CN 1310620 A CN1310620 A CN 1310620A CN 99808983 A CN99808983 A CN 99808983A CN 99808983 A CN99808983 A CN 99808983A CN 1310620 A CN1310620 A CN 1310620A
Authority
CN
China
Prior art keywords
glucose uptake
human
uptake enhancer
chemical compound
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99808983A
Other languages
English (en)
Chinese (zh)
Inventor
A·M·A·布里尔
R·E·布金哈姆
N·坎杜迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Laboratoires Pharmaceutiques
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Laboratoires Pharmaceutiques
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by SmithKline Beecham Laboratoires Pharmaceutiques, SmithKline Beecham Ltd filed Critical SmithKline Beecham Laboratoires Pharmaceutiques
Publication of CN1310620A publication Critical patent/CN1310620A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN99808983A 1998-07-21 1999-07-21 利用葡萄糖摄入增强剂减少编程性细胞死亡 Pending CN1310620A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9815871.0 1998-07-21
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GB9815872.8 1998-07-21
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
GB9905387.8 1999-03-09

Publications (1)

Publication Number Publication Date
CN1310620A true CN1310620A (zh) 2001-08-29

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99808983A Pending CN1310620A (zh) 1998-07-21 1999-07-21 利用葡萄糖摄入增强剂减少编程性细胞死亡

Country Status (25)

Country Link
EP (2) EP1098639B1 (enExample)
JP (1) JP2002521326A (enExample)
KR (1) KR20010079551A (enExample)
CN (1) CN1310620A (enExample)
AP (1) AP2001002036A0 (enExample)
AT (1) ATE288746T1 (enExample)
AU (1) AU5053799A (enExample)
BG (1) BG105250A (enExample)
BR (1) BR9912117A (enExample)
CA (1) CA2338211A1 (enExample)
DE (1) DE69923687T2 (enExample)
DK (1) DK1098639T3 (enExample)
EA (1) EA200100165A1 (enExample)
ES (1) ES2237929T3 (enExample)
HU (1) HUP0103199A3 (enExample)
ID (1) ID26986A (enExample)
IL (1) IL140664A0 (enExample)
NO (1) NO20010292L (enExample)
OA (1) OA11579A (enExample)
PL (1) PL345627A1 (enExample)
PT (1) PT1098639E (enExample)
SI (1) SI1098639T1 (enExample)
SK (1) SK1012001A3 (enExample)
TR (1) TR200100207T2 (enExample)
WO (1) WO2000004890A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073600A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
CA2382966A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
EP0958818A1 (en) * 1996-09-12 1999-11-24 Sankyo Company Limited Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
JP2002521326A (ja) 2002-07-16
AU5053799A (en) 2000-02-14
NO20010292D0 (no) 2001-01-18
NO20010292L (no) 2001-03-08
ATE288746T1 (de) 2005-02-15
ID26986A (id) 2001-02-22
PL345627A1 (en) 2002-01-02
OA11579A (en) 2004-06-01
AP2001002036A0 (en) 2001-03-31
HK1037865A1 (en) 2002-02-22
CA2338211A1 (en) 2000-02-03
HUP0103199A2 (hu) 2002-05-29
DE69923687T2 (de) 2006-04-06
SI1098639T1 (enExample) 2005-08-31
HUP0103199A3 (en) 2002-08-28
EP1098639A1 (en) 2001-05-16
EA200100165A1 (ru) 2001-08-27
BR9912117A (pt) 2001-04-10
PT1098639E (pt) 2005-06-30
BG105250A (en) 2001-11-30
IL140664A0 (en) 2002-02-10
KR20010079551A (ko) 2001-08-22
DK1098639T3 (da) 2005-06-13
TR200100207T2 (tr) 2001-05-21
WO2000004890A1 (en) 2000-02-03
EP1516617A2 (en) 2005-03-23
DE69923687D1 (de) 2005-03-17
ES2237929T3 (es) 2005-08-01
SK1012001A3 (en) 2001-08-06
EP1098639B1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
KR100666591B1 (ko) 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
JP2003535898A (ja) 真性糖尿病の治療用のジペプチジルペプチダーゼｉｖ阻害剤および他の抗糖尿病剤の組み合わせ
KR100671918B1 (ko) 티아졸리딘디온, 인슐린 분비촉진제 및 디구아니드를사용한 당뇨병의 치료
JP2002504138A (ja) ロシグリタゾンおよびインスリンを用いる糖尿病の治療
KR100680667B1 (ko) 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
CN1263467A (zh) 用噻唑烷二酮、促胰岛素分泌剂和α一葡糖苷酶抑制剂治疗糖尿病
CN1310619A (zh) 利用葡萄糖摄入增强剂减小心脏缺血后损伤
CN1310620A (zh) 利用葡萄糖摄入增强剂减少编程性细胞死亡
JP2001523271A (ja) チアゾリジンジオンおよびアルファ−グルコシダーゼ阻害剤を用いる糖尿病の治療
JP2001523270A (ja) チアゾリジンジオンおよびスルホニルウレアを用いる糖尿病の治療
US20020006939A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
US20030069283A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
KR20010024482A (ko) 고혈당증 치료용 티아졸리딘디온의 용도
KR20010024481A (ko) 고혈당증 치료용 티아졸리딘디온의 용도
MXPA00003634A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
AU4586902A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
CN1781483A (zh) 用噻唑烷二酮和二甲双胍治疗糖尿病

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1074761

Country of ref document: HK